Who owns AVALO THERAPEUTICS ORD?
- Ticker: AVTX
- CUSIP Number: 05338f306
Tip: Access positions for across all investors
Analyze quarterly positions in Avalo Therapeutics Ord with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Avalo Therapeutics Ord stock
Who bought or sold AVALO THERAPEUTICS ORD this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| FMR | 2.9M | $43M | 1207% | Mar 2026 |
|
| Caligan Partners | 1.6M | $24M | 85% | Mar 2026 |
|
| BVF | 1.6M | $24M | 20% | Mar 2026 |
|
| venBio Select Advisor | 1.4M | $21M | 100% | Mar 2026 |
|
| Affinity Asset Advisors | 1.3M | $20M | 28% | Mar 2026 |
|
| Logos Global Management | 1.3M | $19M | 100% | Mar 2026 |
|
| Nantahala Capital Management | 1.2M | $18M | 0% | Mar 2026 |
|
| UBS Group | 1.1M | $17M | 139% | Mar 2026 |
|
| Caption Management | 1.1M | $16M | 259% | Mar 2026 |
|
| Point72 Asset Management | 916k | $14M | 46% | Mar 2026 |
|
| Farallon Capital Management | 916k | $14M | 100% | Mar 2026 |
|
| Rtw Investments | 857k | $13M | 100% | Mar 2026 |
|
| Adage Capital Partners GP | 854k | $13M | 55% | Mar 2026 |
|
| Millennium Management | 836k | $13M | 27% | Mar 2026 |
|
| TCG Crossover Management | 738k | $11M | 53% | Mar 2026 |
|
| Balyasny Asset Management | 732k | $11M | 67% | Mar 2026 |
|
| Vanguard Capital Management | 720k | $11M | 100% | Mar 2026 |
|
| RA Capital Management | 663k | $9.9M | 0% | Mar 2026 |
|
| Bank of America Corporation | 643k | $9.6M | 100% | Mar 2026 |
|
| Susquehanna International | 637k | $9.5M | 115% | Mar 2026 |
|
| Ikarian Capital | 560k | $8.4M | 528% | Mar 2026 |
|
| Boothbay Fund Management | 486k | $7.3M | 122% | Mar 2026 |
|
| Commodore Capital | 483k | $7.2M | 0% | Mar 2026 |
|
| OrbiMed Advisors | 475k | $7.1M | -60% | Mar 2026 |
|
| Jennison Associates | 471k | $7.0M | -1% | Mar 2026 |
|
| Soleus Capital Management | 442k | $6.6M | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 423k | $6.3M | 114% | Mar 2026 |
|
| Kennedy Capital Management | 388k | $5.8M | 100% | Mar 2026 |
|
| BlackRock | 327k | $4.9M | 13% | Mar 2026 |
|
| Boxer Capital Management | 300k | $4.5M | 9% | Mar 2026 |
|
| Pivotal bioVenture Partners Investment Advisor | 296k | $4.4M | 100% | Mar 2026 |
|
| Citadel Advisors | 261k | $3.9M | -38% | Mar 2026 |
|
| Seven Fleet Capital Management | 214k | $3.2M | 238% | Mar 2026 |
|
| Jane Street | 194k | $2.9M | 8% | Mar 2026 |
|
| Nan Fung Trinity | 189k | $3.5M | 0% | Jun 2026 |
|
| Velan Capital Investment Management | 185k | $2.8M | -30% | Mar 2026 |
|
| Qube Research & Technologies | 175k | $2.6M | 171% | Mar 2026 |
|
| Ameriprise Financial | 172k | $2.6M | -21% | Mar 2026 |
|
| Standard Life Aberdeen | 172k | $2.6M | 80% | Mar 2026 |
|
| Geode Capital Management | 170k | $2.5M | 2% | Mar 2026 |
|
| Morgan Stanley | 161k | $2.4M | -39% | Mar 2026 |
|
| Hudson Bay Capital Management | 161k | $2.4M | 861% | Mar 2026 |
|
| Exome Asset Management | 159k | $2.4M | 100% | Mar 2026 |
|
| Deutsche Bank Aktiengesellschaft | 150k | $2.2M | 0% | Mar 2026 |
|
| Perceptive Advisors | 140k | $2.1M | 0% | Mar 2026 |
|
| Stempoint Capital | 135k | $2.0M | -1% | Mar 2026 |
|
| Marshall Wace | 129k | $1.9M | -75% | Mar 2026 |
|
| XTX Topco | 127k | $1.9M | 213% | Mar 2026 |
|
| Moody Aldrich Partners | 126k | $2.3M | -21% | Jun 2026 |
|
| Quadrature Capital | 125k | $1.9M | 136% | Mar 2026 |
|
| Dr. Jeffrey R. Jay, M.D. | 125k | $1.9M | 0% | Mar 2026 |
|
| Renaissance Technologies | 120k | $1.8M | 556% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 86k | $1.3M | 100% | Mar 2026 |
|
| Squarepoint Ops | 81k | $1.2M | 99% | Mar 2026 |
|
| Rosalind Advisors | 75k | $1.1M | 100% | Mar 2026 |
|
| State Street Corporation | 72k | $1.1M | -10% | Mar 2026 |
|
| Two Sigma Investments | 64k | $962k | -57% | Mar 2026 |
|
| Longwood Capital Partners | 61k | $908k | 100% | Mar 2026 |
|
| Goldman Sachs Group | 60k | $897k | -8% | Mar 2026 |
|
| HighVista Strategies | 59k | $875k | -39% | Mar 2026 |
|
| Sei Investments | 57k | $849k | 100% | Mar 2026 |
|
| 683 Capital Management | 57k | $849k | 0% | Mar 2026 |
|
| Wells Fargo & Company | 52k | $778k | 100% | Mar 2026 |
|
| TD Asset Management | 51k | $768k | 100% | Mar 2026 |
|
| DLD Asset Management | 50k | $743k | -35% | Mar 2026 |
|
| Hrt Financial | 48k | $718k | 100% | Mar 2026 |
|
| Man Group | 47k | $695k | 100% | Mar 2026 |
|
| Dimensional Fund Advisors | 41k | $610k | 100% | Mar 2026 |
|
| Springbok Capital Management | 35k | $524k | 100% | Mar 2026 |
|
| Northern Trust | 31k | $456k | -5% | Mar 2026 |
|
| EntryPoint Capital | 30k | $449k | 100% | Mar 2026 |
|
| Aquatic Capital Management | 30k | $444k | 100% | Mar 2026 |
|
| Artia Global Partners | 29k | $433k | -30% | Mar 2026 |
|
| Glenmede Trust Company | 26k | $384k | 26% | Mar 2026 |
|
| Envestnet Asset Management | 20k | $299k | 25% | Mar 2026 |
|
| Brevan Howard Capital Management | 19k | $289k | 100% | Mar 2026 |
|
| Susquehanna Portfolio Strategies | 17k | $257k | 100% | Mar 2026 |
|
| Westfield Capital Management Company | 16k | $234k | 100% | Mar 2026 |
|
| Barclays | 15k | $219k | -86% | Mar 2026 |
|
| Jump Financial | 13k | $191k | -2% | Mar 2026 |
|
| OMERS Administration Corporation | 12k | $176k | -40% | Mar 2026 |
|
| Shay Capital | 10k | $152k | 100% | Mar 2026 |
|
| Charles Schwab Investment Management | 10k | $149k | 100% | Mar 2026 |
|
| Persistent Asset Partners | 7.9k | $118k | -48% | Mar 2026 |
|
| Vanguard Global Advisers | 5.6k | $84k | 100% | Mar 2026 |
|
| PFS Partners | 2.0k | $30k | 0% | Mar 2026 |
|
| Royal Bank of Canada | 216.00 | $0 | 100% | Mar 2026 |
|
| Fortitude Family Office | 63.00 | $940.999500 | 100% | Mar 2026 |
|
| EverSource Wealth Advisors | 35.00 | $646.999500 | 0% | Jun 2026 |
|
| Activest Wealth Management | 1.00 | $18.000000 | 0% | Jun 2026 |
|
| Key FInancial | 1.00 | $18.000000 | 0% | Jun 2026 |
|
| Silver Grove Financial Group | 1.00 | $15.000000 | 100% | Mar 2026 |
|
| Parallel Advisors | 1.00 | $15.000000 | 0% | Mar 2026 |
|
| Advisor Group Holdings | 1.00 | $14.000000 | 0% | Mar 2026 |
|
Who sold out of Avalo Therapeutics Ord?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Silverarc Capital Management | Dec 2025 | 524k | $9.5M |
| Patient Square Capital | Dec 2025 | 312k | $5.7M |
| Jain Global | Dec 2025 | 217k | $3.9M |
| SummitTX Capital | Dec 2025 | 196k | $3.6M |
| Superstring Capital Management | Dec 2025 | 153k | $2.8M |
| Fred Alger Management | Dec 2025 | 80k | $1.5M |
| Sio Capital Management | Dec 2025 | 72k | $1.3M |
| Woodline Partners | Dec 2025 | 52k | $945k |
| Atom Investors | Dec 2025 | 51k | $930k |
| Two Sigma Advisers | Dec 2025 | 49k | $897k |
| Walleye Trading Advisors | Dec 2025 | 42k | $757k |
| ExodusPoint Capital Management | Dec 2025 | 32k | $586k |
| Belvedere Trading | Dec 2025 | 17k | $317k |
| AlphaCentric Advisors | Mar 2026 | 12k | $174k |
| Tower Research Capital | Dec 2025 | 8.7k | $159k |
| Acadian Asset Management | Dec 2025 | 1.5k | $26k |
| Farther Finance Advisors | Mar 2026 | 75.00 | $1.3k |
| Group One Trading | Dec 2025 | 1.00 | $18.000000 |